Navigation Links
David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
Date:4/21/2008

David S. Tierney, M.D. joins Connecticut office to Focus on Specialty

Pharmaceuticals, Drug Delivery and Biotechnology

STAMFORD, Conn., April 21 /PRNewswire/ -- Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that David S. Tierney, M.D., has joined as an Entrepreneur-in-Residence in the firm's Connecticut office. Most recently, Dr. Tierney was president and chief executive officer of Valera Pharmaceuticals, Inc., a fully-integrated specialty pharmaceutical and drug delivery company, which was acquired by Indevus Pharmaceuticals.

"David's background is perfect for this role. He has experience as a chief executive with an entrepreneurial company, and also as a drug developer in both specialty and mainstream markets," said Alex Zisson, partner. "We're looking forward to working with David on ideas for new companies and potential investments."

Dr. Tierney has more than 18 years of drug development experience, most recently as chief executive officer of Valera Pharmaceuticals, Inc. Prior to joining Valera, he was president of Biovail Technologies, overseeing all research, development, clinical and regulatory affairs. Prior to Biovail, Dr. Tierney was senior vice president, drug development for Roberts Pharmaceuticals, which was acquired by Shire plc. He began his pharmaceutical career at Elan Corporation where he spent eight years in various drug development roles. Dr. Tierney is also a member of the board of directors of Catalyst Pharmaceuticals Partners, Inc, Nexmed Inc and serves as chairman of the board of directors of Bioject Inc.

"Thomas, McNerney & Partners has a great platform in biopharmaceuticals," said Dr. Tierney. "The partners have many contacts in industry and academia, and I'm confident that I'll be able to add value to their investment process while we work together to identify my next operating role."

<
'/>"/>
SOURCE Thomas, McNerney & Partners, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... July 28, 2015  Faced with increasing challenges ... palliative rather than symptomatic, the global healthcare industry ... therapies capable of curing or significantly changing the ... to look towards regenerative medicine as a viable ... paradigm in human health with the potential to ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... state of the Biophotonics industry.The report provides a basic overview of the industry ... provided for the international markets including development trends, competitive landscape analysis, and key ...
(Date:7/27/2015)... ATLANTA , July 27, 2015 Research ... Lab Expo will expand on the studies that led ... only rapid diagnostic for this disease to receive approval ... prove vital to breaking Ebola,s grip on ... within minutes, and enabling healthcare workers to isolate and ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... 6, 2012 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the 14th ... The live presentation takes place on Monday, February ... Time.  The presentation will be webcast and may be accessed ...
... 6, 2012  BioStorage Technologies, a global provider of ... chain logistics for the bioscience industry, will host ... in Clinical Trials on Tuesday, March 6, 2012 ... The 2-hour workshop will focus ...
... 2012 UV Flu Technologies, Inc. ( OTCBB: ... ahead of schedule in its continuing program to eliminate all debt. ... the remaining and final convertible note, in the amount of $32,500 ... we have made in the last twelve months is nothing short ...
Cached Biology Technology:BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... TORONTO, ON Psychologists at the University of ... interaction has the ability to influence an individual,s sensitivity ... clinical implications for doctor-patient relationships and the general well-being ... of studies over the past several decades have demonstrated ...
... CHICAGO --- Northwestern Medicine researchers at the Robert H. ... a new, nontoxic drug made from a chemical in soy ... to the rest of the body. These findings will ... Research Frontiers in Cancer Prevention Research Conference. Genistein, a ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
Cached Biology News:Psychologists identify influence of social interaction on sensitivity to physical pain 2Soy may stop prostate cancer spread 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2
... The dual-bay DNA Engine Dyad ... for DNA amplification (PCR). The chassis ... units (sample-holder, heat-pump assemblies), which hold ... Color display offers graphical programming with ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
Biology Products: